Literature DB >> 1339315

Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein.

M K Spriggs1, D E Hruby, C R Maliszewski, D J Pickup, J E Sims, R M Buller, J VanSlyke.   

Abstract

Supernatants from vaccinia virus (VV)-infected CV-1 cells were examined and found to contain a 33 kd protein capable of binding murine interleukin-1 beta (mIL-1 beta). A VV open reading frame (ORF) that exhibits 30% amino acid identity to the type II IL-1 receptor was expressed in CV-1-EBNA cells and shown specifically to bind mIL-1 beta. A similar ORF from cowpox virus was expressed and also specifically bound mIL-1 beta. A recombinant VV was constructed in which this ORF was disrupted (vB15RKO). Supernatants from vB15RKO-infected cells did not contain an IL-1-binding protein. Supernatants from VV-infected CV-1 cells were capable of inhibiting IL-1-induced murine lymphocyte proliferation in vitro while supernatants from vB15RKO infected cells did not. Intracranial inoculation of mice with vB15RKO suggests that this ORF is involved in VV virulence. The possible role of a virus-encoded IL-1-binding protein in the pathology of a poxvirus infection and its relationship to other poxvirus-encoded immune modulators is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1339315     DOI: 10.1016/0092-8674(92)90273-f

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  84 in total

Review 1.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  Host-pathogen interactions: subversion and utilization of the NF-kappa B pathway during infection.

Authors:  C M Tato; C A Hunter
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

4.  Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Authors:  Shawn S Jackson; Petr Ilyinskii; Valérie Philippon; Linda Gritz; Alicia Gómez Yafal; Kimberly Zinnack; Kristin R Beaudry; Kelledy H Manson; Michelle A Lifton; Marcelo J Kuroda; Norman L Letvin; Gail P Mazzara; Dennis L Panicali
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Molecular characterization and determination of the coding capacity of the genome of equine herpesvirus type 2 between the genome coordinates 0.235 and 0.258 (the EcoRI DNA fragment N; 4.2 kbp).

Authors:  H J Rode; J J Bugert; M Handermann; P Schnitzler; R Kehm; W Janssen; H Delius; G Darai
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

6.  Ectromelia virus encodes a BTB/kelch protein, EVM150, that inhibits NF-κB signaling.

Authors:  Qian Wang; Kristin Burles; Brianne Couturier; Crystal M H Randall; Joanna Shisler; Michele Barry
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

7.  Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes.

Authors:  V Kapur; M W Majesky; L L Li; R A Black; J M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  Down-regulation of major histocompatibility complex class I synthesis by murine cytomegalovirus early gene expression.

Authors:  A E Campbell; J S Slater
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 9.  Biomimetic strategies based on viruses and bacteria for the development of immune evasive biomaterials.

Authors:  Matthew T Novak; James D Bryers; William M Reichert
Journal:  Biomaterials       Date:  2009-01-29       Impact factor: 12.479

10.  Interleukin 1 signaling occurs exclusively via the type I receptor.

Authors:  J E Sims; M A Gayle; J L Slack; M R Alderson; T A Bird; J G Giri; F Colotta; F Re; A Mantovani; K Shanebeck
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.